Online inquiry

IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3907MR)

This product GTTS-WQ3907MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3907MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7116MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ1591MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ7945MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ1563MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ1231MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ6759MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ14063MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ7230MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW